• 
• 

Product Pipeline

Asubio has an active portfolio of investigational compounds in development in the United States. Following is an overview of new drug candidates, their target indications and phase of clinical development.

Entity	Phase of Development	Indication	Status
Carperitide	III	AMI	Available for Licensing
Piclozotan	II	Stroke	Available for Licensing
Piclozotan	II	Motor Complications Parkinson’s Disease	Clinical Development
SUN11031	II	Cachexia	Clinical Development
---	I	Dermatologic Condition	Clinical Development
---	Pre-IND	CNS/CV Disorders	Planning

Carperitide is a recombinant form of human atrial natriuretic peptide (hANP) that is currently available for licensing. While the major pharmacological effects of natriuretic peptides are known to be vasorelaxation and natriuresis, emerging evidence suggests that carperitide, when administered at doses that are considered sub-hemodynamic, may have a direct protective effect on cardiomyocytes under conditions consistent with ischemia/reperfusion - related injury in acute myocardial infarction (AMI).

Ischemic heart disease is one of the main causes of chronic heart failure, a major cause of morbidity and mortality worldwide. There are more than 850,000 new or recurrent AMIs each year in the U.S. alone. Ischemia/reperfusion-related sequelae occurring by discharge play a significant role in the long-term morbidity and mortality associated with AMI. Few medications, however, have been shown to decrease ischemia or reperfusion injury. Recent clinical studies have provided evidence that carperitide administration can significantly reduce myocardial damage after AMI. Scientific data supports further development of carperitide as adjunct therapy to PCI in the acute treatment of myocardial infarction.

Back to Top

SUN11031 is a peptide hormone currently under Phase II investigation for the treatment of cachexia. Cachexia is the accelerated loss of tissue, primarily skeletal muscle, in the context of a chronic inflammatory response to many chronic or end-stage diseases. Clinically cachexia is characterized by weakness and a noticeable and progressive loss of body weight, fat, and muscle, and is a condition distinct from starvation. The largest cachexia patient populations are found in patients with COPD, chronic heart failure (CHF) and cancer. Similar changes have also been observed in the elderly. In COPD, CHF and cancer, 15% or more of patients suffer from cachexia associated with their condition. These patients experience both increased morbidity and mortality due to their cachexia, and unfortunately, few treatment options exist that both increase muscle mass and improve functional performance. SUN11031 has multiple activities that are expected to be beneficial in the treatment of cachexia.

Back to Top